CoChat

Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence

Open access
Losa, Marco, Castellino, Laura, Pagnano, Angela, Rossini, Alessandro, Mortini, Pietro, Lanzi, Roberto · 2020 · The Journal of Clinical Endocrinology & Metabolism
Cited by 42

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Context: Recombinant human growth hormone (rhGH) replacement therapy is often prescribed in patients with nonfunctioning pituitary adenoma (NFPA) or craniopharyngioma, Objective: To study whether rhGH therapy in patients with adult growth hormone deficiency (AGHD) increases the risk of pituitary tumor recurrence. Design: Retrospective, observational study. Setting: Tertiary care center. Patients: We studied 283 consecutive patients with AGHD due to NFPA or craniopharyngioma between 1995 and 2018. Intervention: rhGH treatment at standard doses was initiated in 123 patients (43.5%). The remaining 160 patients served as controls. Main Outcome Measure: Risk of tumor recurrence in rhGH-treated and control patients. Results: In univariate analysis, recurrence of the pituitary tumor was less frequent in rhGH-treated patients (19.5%) than in controls (29.7%; hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.32–0.86; P = .01). Multivariate Cox analysis demonstrated that the risk of tumor recurrence was associated with detection of residual disease at the baseline magnetic resonance imaging (HR 9.17; 95% CI, 4.88–17.22; P < .001) and not having performed radiotherapy (HR 16.97; 95% CI, 7.55–38.16; P < .001), while rhGH treatment was no longer associated with a lower risk of recurrence (HR 0.82; 95% CI, 0.47–1.44; P = .50). Conclusions: We found no association between rhGH replacement and the risk of tumor recurrence in patients with AGHD caused by NFPA or craniopharyngioma. These data add to the mounting evidence that rhGH therapy has a neutral effect on the recurrence of pituitary tumors. Précis: Replacement therapy with rhGH is prescribed to patients with adult growth hormone deficiency. Our study found no increased risk of pituitary tumor recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaa089

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 42

Metadata

Authors
Losa, M., Castellino, L., Pagnano, A., Rossini, A., Mortini, P., & Lanzi, R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2020-02-29
Volume
105
Issue
5
Pages
1573-1580
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3007254418
Cited by
42
References
5
FWCI
4.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. https://app.cochat.ai/papers/10.1210/clinem/dgaa089
The paper
Losa, M., Castellino, L., Pagnano, A., Rossini, A., Mortini, P., & Lanzi, R. (2020). Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa089

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.